Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 246-255 , February 2008

Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders

  • Ginna G. Laport

      Affiliations

    • Stanford University Medical Center, Stanford, California
    • Corresponding Author InformationCorrespondence and reprint requests: Ginna G. Laport, MD, Division of Blood and Marrow Transplantation, Stanford University Medical Center, 300 Pasteur Drive, Rm H3249, Stanford, CA 94305-5623.
    • ,
  • Brenda M. Sandmaier

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Barry E. Storer

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Bart L. Scott

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Monic J. Stuart

      Affiliations

    • Stanford University Medical Center, Stanford, California
    • ,
  • Thoralf Lange

      Affiliations

    • University of Leipzig, Leipzig, Germany
    • ,
  • Michael B. Maris

      Affiliations

    • Veterans Affairs Puget Sound Health Care System, Seattle, Washington
    • ,
  • Edward D. Agura

      Affiliations

    • Baylor University Medical Center, Dallas, Texas
    • ,
  • Thomas R. Chauncey

      Affiliations

    • Veterans Affairs Puget Sound Health Care System, Seattle, Washington
    • ,
  • Ruby M. Wong

      Affiliations

    • Stanford University Medical Center, Stanford, California
    • ,
  • Stephen J. Forman

      Affiliations

    • City of Hope National Medical Center, Duarte, California
    • ,
  • Finn B. Petersen

      Affiliations

    • University of Utah, Salt Lake City, Utah
    • ,
  • James C. Wade

      Affiliations

    • Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Elliot Epner

      Affiliations

    • University of Arizona, Tucson, Arizona
    • ,
  • Benedetto Bruno

      Affiliations

    • University of Torino, Torino, Italy
    • ,
  • Wolfgang A. Bethge

      Affiliations

    • University of Tuebingen, Tuebingen, Germany
    • ,
  • Peter T. Curtin

      Affiliations

    • Oregon Health Sciences University, Portland, Oregon
    • ,
  • David G. Maloney

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Karl G. Blume

      Affiliations

    • Stanford University Medical Center, Stanford, California
    • ,
  • Rainer F. Storb

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington

References 

  1. de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110:620–630
  2. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997–2004
  3. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912–3918
  4. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93:2831–2838
  5. Witherspoon RP, Deeg HJ, Storer B, et al. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol. 2001;19:2134–2141
  6. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20:128–135
  7. Giaccone L, McCune JS, Maris MB, et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood. 2005;106:4381–4388
  8. Maris MB, Sandmaier BM, Storer BE, et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant. 2006;12:454–465
  9. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304
  10. Sullivan K. Graft-vs-host-disease. In:  Blume KG,  Forman SJ,  Applebaum FR editor. Hematopoietic cell transplantation. 3rd ed.. Oxford, UK: Blackwell Publishing Ltd; 2004;p. 635–664
  11. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104:1616–1623
  12. Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21:255–261
  13. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–846
  14. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105:1810–1814
  15. Martino R, van Biezen A, Iacobelli S, et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from HLA-identical siblings in adults with myelodysplastic syndromes: a comparison with standard myeloablative conditioning: a study of the EBMT-Chronic Leukemia Working Party. Blood. 2003;102:184a
  16. Kroger N, Bornhauser M, Ehninger G, et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol. 2003;82:336–342
  17. Taussig DC, Davies AJ, Cavenagh JD, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol. 2003;21:3060–3065
  18. Wong R, Giralt SA, Martin T, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003;102:3052–3059
  19. Chan GW, Foss FM, Klein AK, et al. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:753–759
  20. Martino R, Caballero MD, Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood. 2002;100:2243–2245
  21. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–864
  22. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021–2030
  23. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993–2003
  24. Oran B, Giralt S, Saliba R, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007;13:454–462
  25. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 1997;89:2578–2585
  26. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood. 1996;88:358–365
  27. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99:840–849
  28. Kerbauy DM, Chyou F, Gooley T, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2005;11:713–720
  29. Kroger N, Zabelina T, Guardiola P, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2002;118:67–73
  30. Elliott MA, Tefferi A, Hogan WJ, et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2006;37:1003–1008
  31. Estey EH. Prognosis and therapy of secondary myelodysplastic syndromes. Haematologica. 1998;83:543–549
  32. Ballen KK, Gilliland DG, Guinan EC, et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant. 1997;20:737–743
  33. Ditschkowski M, Beelen DW, Trenschel R, et al. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant. 2004;34:807–813
  34. Daly A, Song K, Nevill T, et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant. 2003;32:35–40
  35. Pagel JM, Appelbaum FR, Sandmaier BM, et al. 131 I-Anti-CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patient with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Blood. 2005;106:119a

PII: S1083-8791(07)00575-7

doi: 10.1016/j.bbmt.2007.11.012

Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 246-255 , February 2008

Article Tools

* Image Usage & Resolution